These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 23523357)
1. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas. Bai J; Gui S; Zhang Y J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357 [TBL] [Abstract][Full Text] [Related]
2. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells. Cao L; Gao H; Li P; Gui S; Zhang Y Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas. Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437 [TBL] [Abstract][Full Text] [Related]
4. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line. Lv H; Li C; Gui S; Sun M; Li D; Zhang Y J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755 [TBL] [Abstract][Full Text] [Related]
5. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models. Cao L; Gao H; Gui S; Bai G; Lu R; Wang F; Zhang Y J Neurooncol; 2014 Feb; 116(3):523-31. PubMed ID: 24407733 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients. Wang CJ; Guo DK; You TG; Shen DW; Wang C; Tang L; Wang J; Xu RH; Zhang H Mol Med Rep; 2014 Dec; 10(6):3125-31. PubMed ID: 25270093 [TBL] [Abstract][Full Text] [Related]
7. Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line. Leng L; Zhang Y J Clin Neurosci; 2011 Dec; 18(12):1694-8. PubMed ID: 22015101 [TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1. Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446 [TBL] [Abstract][Full Text] [Related]
9. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas. Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603 [TBL] [Abstract][Full Text] [Related]
10. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904 [TBL] [Abstract][Full Text] [Related]
11. Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism. Li C; Sun Z; Gui S; Liu F; Zhang Y Neuro Endocrinol Lett; 2009; 30(2):268-74. PubMed ID: 19675520 [TBL] [Abstract][Full Text] [Related]
12. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models. Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548 [TBL] [Abstract][Full Text] [Related]
13. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat. Yonezawa K; Tamaki N; Kokunai T Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588 [TBL] [Abstract][Full Text] [Related]
14. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models. Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868 [TBL] [Abstract][Full Text] [Related]
15. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway. Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548 [TBL] [Abstract][Full Text] [Related]
16. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas. Geng X; Ma L; Li Z; Li Z; Li J; Li M; Wang Q; Chen Z; Sun Q World Neurosurg; 2017 Apr; 100():407-416. PubMed ID: 28137551 [TBL] [Abstract][Full Text] [Related]
17. ESR1 and its antagonist fulvestrant in pituitary adenomas. Gao H; Xue Y; Cao L; Liu Q; Liu C; Shan X; Wang H; Gu Y; Zhang Y Mol Cell Endocrinol; 2017 Mar; 443():32-41. PubMed ID: 28043824 [TBL] [Abstract][Full Text] [Related]
18. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy. Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065 [TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender. Lv H; Li C; Gui S; Zhang Y J Endocrinol Invest; 2012 Feb; 35(2):174-80. PubMed ID: 21422801 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profile of bromocriptine-resistant prolactinomas. Wu ZB; Li WQ; Lin SJ; Wang CD; Cai L; Lu JL; Chen YX; Su ZP; Shang HB; Yang WL; Zhao WG Mol Cell Endocrinol; 2014 Sep; 395(1-2):10-8. PubMed ID: 25064468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]